Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Killer-cell immunoglobulin-like receptors define a potent effector program in human γδ T cells
Mahya Razmi, Yeganeh Almasi, Marilee Larrivée, Jonathan B. Angel, Alexandre Blais, Zakia Djaoud
Mahya Razmi, Yeganeh Almasi, Marilee Larrivée, Jonathan B. Angel, Alexandre Blais, Zakia Djaoud
View: Text | PDF
Research Article Hematology Immunology

Killer-cell immunoglobulin-like receptors define a potent effector program in human γδ T cells

  • Text
  • PDF
Abstract

Human γδ T cells are a rare but functionally diverse lymphocyte subset critical for tumor surveillance and antimicrobial immunity. Although they express NK cell–associated receptors such as killer-cell immunoglobulin-like receptors (KIRs), the relevance of KIR expression on γδ T cells remains largely unexplored. Using flow cytometry, ATAC-seq, and RNA-seq, we identified KIR expression as a marker that distinguished 2 functionally and molecularly distinct γδ T cell subsets. KIR+ γδ T cells exhibited an advanced, memory-like differentiation state characterized by heightened cytotoxicity, stable epigenetic remodeling, and a predominant IFN-γ–producing profile. In contrast, KIR– γδ T cells maintained a naive-like phenotype and preferentially produced IL-17 upon polarization. Notably, KIR+ γδ T cells were consistently observed across individuals but were significantly enriched in cytomegalovirus (CMV)-seropositive donors, suggesting that chronic antigenic stimulation could promote the emergence of KIR+ effector γδ T cells. These findings reveal a functional dichotomy in human γδ T cells defined by KIR expression, linking IFN-γ–driven cytotoxicity with KIR+ cells and IL-17 production with KIR– cells. This insight advances our understanding of γδ T cell heterogeneity and has implications for viral immunity, immune memory, and the development of γδ T cell–based immunotherapies.

Authors

Mahya Razmi, Yeganeh Almasi, Marilee Larrivée, Jonathan B. Angel, Alexandre Blais, Zakia Djaoud

×

Figure 6

KIR– γδ T cells show increased RORγt and IL-17 expression after polarization.

Options: View larger image (or click on image) Download as PowerPoint
KIR– γδ T cells show increased RORγt and IL-17 expression after polariza...
(A–C) αβ T cell–depleted PBMCs were cultured for 4 days with IL-1β, IL-6, IL-23, and TGF-β (A and B) or for 10 days in the same cytokine cocktail supplemented with irradiated allogeneic PBMC feeder cells (C). (A and B) Representative overlaid histograms (left panels) and corresponding violin plots (right panels) compare RORγt and IL-17 expression between KIR– and KIR+ γδ T cells after 4 days of polarization. (C) Representative overlaid histograms (top panels) and corresponding violin plots (bottom panel) show KIR expression at Day 0 and Day 10 of polarization. Each dot represents an individual donor (n = 12, A; n = 8, B and C). Statistical significance of the difference between KIR– and KIR+ subsets was assessed using the paired 2-tailed t test (*P < 0.05, **P < 0.005).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts